

# Global NK-1 Receptor Antagonists Market Growth 2026-2032

<https://marketpublishers.com/r/G104CCE1482FEN.html>

Date: March 2026

Pages: 133

Price: US\$ 3,660.00 (Single User License)

ID: G104CCE1482FEN

## Abstracts

The global NK-1 Receptor Antagonists market size is predicted to grow from US\$ 834 million in 2025 to US\$ 1333 million in 2032; it is expected to grow at a CAGR of 7.1% from 2026 to 2032.

NK-1 receptor antagonists are a class of drugs that block the neurokinin-1 (NK1) receptors, which are activated by the neurotransmitter substance P. Substance P plays a key role in the body's vomiting reflex, as well as in pain perception and stress responses. By inhibiting NK1 receptors, these drugs are primarily used to prevent and treat nausea and vomiting, particularly those caused by chemotherapy, radiation therapy, or surgery. In 2024, the global sales volume of NK-1 receptor antagonists reached 3.65 million units, with an average price of 220 USD per unit.

## Regional Market Landscape

NK-1 receptor antagonists exhibit a distinct regional distribution in the global market. North America accounts for 45% of the total market, driven primarily by the mature pharmaceutical R&D infrastructure and high treatment demand in the United States. Europe follows with a 28% share, led by Germany, France, and the United Kingdom, where healthcare insurance coverage and acceptance of innovative drugs are high. The Asia-Pacific region holds 20% of the market, with China, Japan, and India as core contributors, reflecting steady growth in demand due to the increasing prevalence of chronic diseases and cancer. Latin America and the Middle East & Africa together represent 7%, primarily supported by Brazil, Mexico, and South Africa, where market development is relatively slower due to limited healthcare coverage but potential for growth exists.

## Key Manufacturers and Industry Competition

The NK-1 receptor antagonist industry demonstrates an oligopolistic competitive structure. Major manufacturers include global companies such as Merck, Glenmark, and Sandoz, alongside regional players like Fosun Pharma and Hengrui Medicine in China. Upstream, these companies rely on raw material suppliers such as Lonza and WuXi AppTec, while downstream distribution channels include hospitals, pharmacy chains, and specialized medical institutions. Competition extends beyond pricing and sales networks, focusing also on R&D pipelines and expansion into new indications. Strategic partnerships, mergers, and licensing agreements are employed to integrate the supply chain, enhance market share, and strengthen technological barriers.

## Technology Trends and Innovation Directions

Technological development in NK-1 receptor antagonists focuses on improving drug selectivity, prolonging half-life, and enhancing oral bioavailability. Molecular design and structural optimization are central to R&D, leveraging high-throughput screening and computer-aided drug design to increase target affinity and specificity. Innovation in delivery systems, including nanoparticle carriers and long-acting formulations, aims to improve patient adherence. Future innovations also involve combination therapies with other mechanisms and the development of personalized medicine approaches to meet the needs of diverse patient populations.

## Policy and Industry Development Drivers

Healthcare policies and regulatory frameworks play a key role in the development of the NK-1 receptor antagonist market worldwide. The United States and Europe maintain strict but transparent approval systems that accelerate the launch of innovative drugs, while China encourages R&D through policies supporting innovation and generic consistency evaluation. Reimbursement policies and patient affordability directly affect market penetration, while updates to clinical guidelines and health management programs indirectly expand demand. Policy support and industry standardization drive higher market concentration and accelerate technological innovation.

## Future Outlook

With the global increase in chronic disease and cancer patient populations, the NK-1 receptor antagonist market is expected to maintain steady long-term growth. Technological innovation will enhance drug efficacy, improve patient adherence, and

reduce side effects and treatment costs. Integration of the supply chain and international expansion will strengthen corporate competitiveness, and regional market differentiation strategies will become a focus for development. Overall, the industry outlook is positive, with the next decade likely to be dominated by high-value innovative drugs alongside cross-border collaboration and regional market expansion.

LP Information, Inc. (LPI) ' newest research report, the “NK-1 Receptor Antagonists Industry Forecast” looks at past sales and reviews total world NK-1 Receptor Antagonists sales in 2025, providing a comprehensive analysis by region and market sector of projected NK-1 Receptor Antagonists sales for 2026 through 2032. With NK-1 Receptor Antagonists sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world NK-1 Receptor Antagonists industry.

This Insight Report provides a comprehensive analysis of the global NK-1 Receptor Antagonists landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on NK-1 Receptor Antagonists portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global NK-1 Receptor Antagonists market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for NK-1 Receptor Antagonists and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global NK-1 Receptor Antagonists.

This report presents a comprehensive overview, market shares, and growth opportunities of NK-1 Receptor Antagonists market by product type, application, key manufacturers and key regions and countries.

### **Segmentation by Type:**

Aprepitant

Rolapitant

Fosaprepitant

Netupitant

Maropitant

Other

**Segmentation by Application:**

Chemotherapy-induced Nausea and Vomiting (CINV)

Postoperative Nausea and Vomiting (PONV)

Other

**This report also splits the market by region:**

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Merck

TerSera Therapeutics

Helsinn Healthcare

Heron Therapeutics

Sandoz

Glenmark

Torrent Pharmaceuticals

Sterisience

Mylan

Fresenius

MSN

Teva

Eugia Pharma

Lupin

Dr. Reddy's Laboratories

Chia Tai Tianqing Pharmaceutical

Qilu Pharmaceutical

Beijing Sihuan Pharmaceutical

Yichang Humanwell Pharmaceutical

Hansoh Pharma

### **Key Questions Addressed in this Report**

What is the 10-year outlook for the global NK-1 Receptor Antagonists market?

What factors are driving NK-1 Receptor Antagonists market growth, globally and by

region?

Which technologies are poised for the fastest growth by market and region?

How do NK-1 Receptor Antagonists market opportunities vary by end market size?

How does NK-1 Receptor Antagonists break out by Type, by Application?

**The report requires updating with new data and is sent in 48 hours after order is placed.**

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

### 2 EXECUTIVE SUMMARY

#### 2.1 World Market Overview

- 2.1.1 Global NK-1 Receptor Antagonists Annual Sales 2021-2032
- 2.1.2 World Current & Future Analysis for NK-1 Receptor Antagonists by Geographic Region, 2021, 2025 & 2032
- 2.1.3 World Current & Future Analysis for NK-1 Receptor Antagonists by Country/Region, 2021, 2025 & 2032

#### 2.2 NK-1 Receptor Antagonists Segment by Type

- 2.2.1 Aprepitant
- 2.2.2 Rolapitant
- 2.2.3 Fosaprepitant
- 2.2.4 Netupitant
- 2.2.5 Maropitant
- 2.2.6 Other
- 2.2.7 NK-1 Receptor Antagonists Sales by Type
  - 2.2.7.1 Global NK-1 Receptor Antagonists Sales Market Share by Type (2021-2026)
  - 2.2.7.2 Global NK-1 Receptor Antagonists Revenue and Market Share by Type (2021-2026)
  - 2.2.7.3 Global NK-1 Receptor Antagonists Sale Price by Type (2021-2026)

#### 2.3 NK-1 Receptor Antagonists Segment by Application

- 2.3.1 Chemotherapy-induced Nausea and Vomiting (CINV)
- 2.3.2 Postoperative Nausea and Vomiting (PONV)
- 2.3.3 Other
- 2.3.4 NK-1 Receptor Antagonists Sales by Application
  - 2.3.4.1 Global NK-1 Receptor Antagonists Sale Market Share by Application

(2021-2026)

2.3.4.2 Global NK-1 Receptor Antagonists Revenue and Market Share by Application

(2021-2026)

2.3.4.3 Global NK-1 Receptor Antagonists Sale Price by Application (2021-2026)

### **3 GLOBAL BY COMPANY**

3.1 Global NK-1 Receptor Antagonists Breakdown Data by Company

3.1.1 Global NK-1 Receptor Antagonists Annual Sales by Company (2021-2026)

3.1.2 Global NK-1 Receptor Antagonists Sales Market Share by Company

(2021-2026)

3.2 Global NK-1 Receptor Antagonists Annual Revenue by Company (2021-2026)

3.2.1 Global NK-1 Receptor Antagonists Revenue by Company (2021-2026)

3.2.2 Global NK-1 Receptor Antagonists Revenue Market Share by Company

(2021-2026)

3.3 Global NK-1 Receptor Antagonists Sale Price by Company

3.4 Key Manufacturers NK-1 Receptor Antagonists Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers NK-1 Receptor Antagonists Product Location Distribution

3.4.2 Players NK-1 Receptor Antagonists Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

### **4 WORLD HISTORIC REVIEW FOR NK-1 RECEPTOR ANTAGONISTS BY GEOGRAPHIC REGION**

4.1 World Historic NK-1 Receptor Antagonists Market Size by Geographic Region (2021-2026)

4.1.1 Global NK-1 Receptor Antagonists Annual Sales by Geographic Region

(2021-2026)

4.1.2 Global NK-1 Receptor Antagonists Annual Revenue by Geographic Region

(2021-2026)

4.2 World Historic NK-1 Receptor Antagonists Market Size by Country/Region (2021-2026)

4.2.1 Global NK-1 Receptor Antagonists Annual Sales by Country/Region (2021-2026)

4.2.2 Global NK-1 Receptor Antagonists Annual Revenue by Country/Region

(2021-2026)

4.3 Americas NK-1 Receptor Antagonists Sales Growth

4.4 APAC NK-1 Receptor Antagonists Sales Growth

4.5 Europe NK-1 Receptor Antagonists Sales Growth

4.6 Middle East & Africa NK-1 Receptor Antagonists Sales Growth

## **5 AMERICAS**

5.1 Americas NK-1 Receptor Antagonists Sales by Country

5.1.1 Americas NK-1 Receptor Antagonists Sales by Country (2021-2026)

5.1.2 Americas NK-1 Receptor Antagonists Revenue by Country (2021-2026)

5.2 Americas NK-1 Receptor Antagonists Sales by Type (2021-2026)

5.3 Americas NK-1 Receptor Antagonists Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

## **6 APAC**

6.1 APAC NK-1 Receptor Antagonists Sales by Region

6.1.1 APAC NK-1 Receptor Antagonists Sales by Region (2021-2026)

6.1.2 APAC NK-1 Receptor Antagonists Revenue by Region (2021-2026)

6.2 APAC NK-1 Receptor Antagonists Sales by Type (2021-2026)

6.3 APAC NK-1 Receptor Antagonists Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

## **7 EUROPE**

7.1 Europe NK-1 Receptor Antagonists by Country

7.1.1 Europe NK-1 Receptor Antagonists Sales by Country (2021-2026)

7.1.2 Europe NK-1 Receptor Antagonists Revenue by Country (2021-2026)

7.2 Europe NK-1 Receptor Antagonists Sales by Type (2021-2026)

7.3 Europe NK-1 Receptor Antagonists Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

## **8 MIDDLE EAST & AFRICA**

8.1 Middle East & Africa NK-1 Receptor Antagonists by Country

8.1.1 Middle East & Africa NK-1 Receptor Antagonists Sales by Country (2021-2026)

8.1.2 Middle East & Africa NK-1 Receptor Antagonists Revenue by Country (2021-2026)

8.2 Middle East & Africa NK-1 Receptor Antagonists Sales by Type (2021-2026)

8.3 Middle East & Africa NK-1 Receptor Antagonists Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

## **9 MARKET DRIVERS, CHALLENGES AND TRENDS**

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

## **10 MANUFACTURING COST STRUCTURE ANALYSIS**

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of NK-1 Receptor Antagonists

10.3 Manufacturing Process Analysis of NK-1 Receptor Antagonists

10.4 Industry Chain Structure of NK-1 Receptor Antagonists

## **11 MARKETING, DISTRIBUTORS AND CUSTOMER**

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 NK-1 Receptor Antagonists Distributors

11.3 NK-1 Receptor Antagonists Customer

## **12 WORLD FORECAST REVIEW FOR NK-1 RECEPTOR ANTAGONISTS BY GEOGRAPHIC REGION**

12.1 Global NK-1 Receptor Antagonists Market Size Forecast by Region

12.1.1 Global NK-1 Receptor Antagonists Forecast by Region (2027-2032)

12.1.2 Global NK-1 Receptor Antagonists Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global NK-1 Receptor Antagonists Forecast by Type (2027-2032)

12.7 Global NK-1 Receptor Antagonists Forecast by Application (2027-2032)

## **13 KEY PLAYERS ANALYSIS**

13.1 Merck

13.1.1 Merck Company Information

13.1.2 Merck NK-1 Receptor Antagonists Product Portfolios and Specifications

13.1.3 Merck NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 Merck Main Business Overview

13.1.5 Merck Latest Developments

13.2 TerSera Therapeutics

13.2.1 TerSera Therapeutics Company Information

13.2.2 TerSera Therapeutics NK-1 Receptor Antagonists Product Portfolios and Specifications

13.2.3 TerSera Therapeutics NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 TerSera Therapeutics Main Business Overview

13.2.5 TerSera Therapeutics Latest Developments

13.3 Helsinn Healthcare

13.3.1 Helsinn Healthcare Company Information

13.3.2 Helsinn Healthcare NK-1 Receptor Antagonists Product Portfolios and Specifications

13.3.3 Helsinn Healthcare NK-1 Receptor Antagonists Sales, Revenue, Price and

## Gross Margin (2021-2026)

13.3.4 Helsinn Healthcare Main Business Overview

13.3.5 Helsinn Healthcare Latest Developments

## 13.4 Heron Therapeutics

13.4.1 Heron Therapeutics Company Information

13.4.2 Heron Therapeutics NK-1 Receptor Antagonists Product Portfolios and Specifications

13.4.3 Heron Therapeutics NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)

13.4.4 Heron Therapeutics Main Business Overview

13.4.5 Heron Therapeutics Latest Developments

## 13.5 Sandoz

13.5.1 Sandoz Company Information

13.5.2 Sandoz NK-1 Receptor Antagonists Product Portfolios and Specifications

13.5.3 Sandoz NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)

13.5.4 Sandoz Main Business Overview

13.5.5 Sandoz Latest Developments

## 13.6 Glenmark

13.6.1 Glenmark Company Information

13.6.2 Glenmark NK-1 Receptor Antagonists Product Portfolios and Specifications

13.6.3 Glenmark NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)

13.6.4 Glenmark Main Business Overview

13.6.5 Glenmark Latest Developments

## 13.7 Torrent Pharmaceuticals

13.7.1 Torrent Pharmaceuticals Company Information

13.7.2 Torrent Pharmaceuticals NK-1 Receptor Antagonists Product Portfolios and Specifications

13.7.3 Torrent Pharmaceuticals NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)

13.7.4 Torrent Pharmaceuticals Main Business Overview

13.7.5 Torrent Pharmaceuticals Latest Developments

## 13.8 Sterisience

13.8.1 Sterisience Company Information

13.8.2 Sterisience NK-1 Receptor Antagonists Product Portfolios and Specifications

13.8.3 Sterisience NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 Sterisience Main Business Overview

- 13.8.5 Sterisience Latest Developments
- 13.9 Mylan
  - 13.9.1 Mylan Company Information
  - 13.9.2 Mylan NK-1 Receptor Antagonists Product Portfolios and Specifications
  - 13.9.3 Mylan NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.9.4 Mylan Main Business Overview
  - 13.9.5 Mylan Latest Developments
- 13.10 Fresenius
  - 13.10.1 Fresenius Company Information
  - 13.10.2 Fresenius NK-1 Receptor Antagonists Product Portfolios and Specifications
  - 13.10.3 Fresenius NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.10.4 Fresenius Main Business Overview
  - 13.10.5 Fresenius Latest Developments
- 13.11 MSN
  - 13.11.1 MSN Company Information
  - 13.11.2 MSN NK-1 Receptor Antagonists Product Portfolios and Specifications
  - 13.11.3 MSN NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.11.4 MSN Main Business Overview
  - 13.11.5 MSN Latest Developments
- 13.12 Teva
  - 13.12.1 Teva Company Information
  - 13.12.2 Teva NK-1 Receptor Antagonists Product Portfolios and Specifications
  - 13.12.3 Teva NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.12.4 Teva Main Business Overview
  - 13.12.5 Teva Latest Developments
- 13.13 Eugia Pharma
  - 13.13.1 Eugia Pharma Company Information
  - 13.13.2 Eugia Pharma NK-1 Receptor Antagonists Product Portfolios and Specifications
  - 13.13.3 Eugia Pharma NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.13.4 Eugia Pharma Main Business Overview
  - 13.13.5 Eugia Pharma Latest Developments
- 13.14 Lupin
  - 13.14.1 Lupin Company Information

- 13.14.2 Lupin NK-1 Receptor Antagonists Product Portfolios and Specifications
- 13.14.3 Lupin NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.14.4 Lupin Main Business Overview
- 13.14.5 Lupin Latest Developments
- 13.15 Dr. Reddy's Laboratories
  - 13.15.1 Dr. Reddy's Laboratories Company Information
  - 13.15.2 Dr. Reddy's Laboratories NK-1 Receptor Antagonists Product Portfolios and Specifications
  - 13.15.3 Dr. Reddy's Laboratories NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.15.4 Dr. Reddy's Laboratories Main Business Overview
  - 13.15.5 Dr. Reddy's Laboratories Latest Developments
- 13.16 Chia Tai Tianqing Pharmaceutical
  - 13.16.1 Chia Tai Tianqing Pharmaceutical Company Information
  - 13.16.2 Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications
  - 13.16.3 Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.16.4 Chia Tai Tianqing Pharmaceutical Main Business Overview
  - 13.16.5 Chia Tai Tianqing Pharmaceutical Latest Developments
- 13.17 Qilu Pharmaceutical
  - 13.17.1 Qilu Pharmaceutical Company Information
  - 13.17.2 Qilu Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications
  - 13.17.3 Qilu Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.17.4 Qilu Pharmaceutical Main Business Overview
  - 13.17.5 Qilu Pharmaceutical Latest Developments
- 13.18 Beijing Sihuan Pharmaceutical
  - 13.18.1 Beijing Sihuan Pharmaceutical Company Information
  - 13.18.2 Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications
  - 13.18.3 Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.18.4 Beijing Sihuan Pharmaceutical Main Business Overview
  - 13.18.5 Beijing Sihuan Pharmaceutical Latest Developments
- 13.19 Yichang Humanwell Pharmaceutical
  - 13.19.1 Yichang Humanwell Pharmaceutical Company Information

13.19.2 Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications

13.19.3 Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)

13.19.4 Yichang Humanwell Pharmaceutical Main Business Overview

13.19.5 Yichang Humanwell Pharmaceutical Latest Developments

13.20 Hansoh Pharma

13.20.1 Hansoh Pharma Company Information

13.20.2 Hansoh Pharma NK-1 Receptor Antagonists Product Portfolios and Specifications

13.20.3 Hansoh Pharma NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)

13.20.4 Hansoh Pharma Main Business Overview

13.20.5 Hansoh Pharma Latest Developments

## **14 RESEARCH FINDINGS AND CONCLUSION**

## List Of Tables

### LIST OF TABLES

Table 1. NK-1 Receptor Antagonists Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. NK-1 Receptor Antagonists Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Aprepitant

Table 4. Major Players of Rolapitant

Table 5. Major Players of Fosaprepitant

Table 6. Major Players of Netupitant

Table 7. Major Players of Maropitant

Table 8. Major Players of Other

Table 9. Global NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units)

Table 10. Global NK-1 Receptor Antagonists Sales Market Share by Type (2021-2026)

Table 11. Global NK-1 Receptor Antagonists Revenue by Type (2021-2026) & (\$ million)

Table 12. Global NK-1 Receptor Antagonists Revenue Market Share by Type (2021-2026)

Table 13. Global NK-1 Receptor Antagonists Sale Price by Type (2021-2026) & (US\$/Unit)

Table 14. Global NK-1 Receptor Antagonists Sale by Application (2021-2026) & (K Units)

Table 15. Global NK-1 Receptor Antagonists Sale Market Share by Application (2021-2026)

Table 16. Global NK-1 Receptor Antagonists Revenue by Application (2021-2026) & (\$ million)

Table 17. Global NK-1 Receptor Antagonists Revenue Market Share by Application (2021-2026)

Table 18. Global NK-1 Receptor Antagonists Sale Price by Application (2021-2026) & (US\$/Unit)

Table 19. Global NK-1 Receptor Antagonists Sales by Company (2021-2026) & (K Units)

Table 20. Global NK-1 Receptor Antagonists Sales Market Share by Company (2021-2026)

Table 21. Global NK-1 Receptor Antagonists Revenue by Company (2021-2026) & (\$ millions)

Table 22. Global NK-1 Receptor Antagonists Revenue Market Share by Company

(2021-2026)

Table 23. Global NK-1 Receptor Antagonists Sale Price by Company (2021-2026) & (US\$/Unit)

Table 24. Key Manufacturers NK-1 Receptor Antagonists Producing Area Distribution and Sales Area

Table 25. Players NK-1 Receptor Antagonists Products Offered

Table 26. NK-1 Receptor Antagonists Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 27. New Products and Potential Entrants

Table 28. Market M&A Activity & Strategy

Table 29. Global NK-1 Receptor Antagonists Sales by Geographic Region (2021-2026) & (K Units)

Table 30. Global NK-1 Receptor Antagonists Sales Market Share Geographic Region (2021-2026)

Table 31. Global NK-1 Receptor Antagonists Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 32. Global NK-1 Receptor Antagonists Revenue Market Share by Geographic Region (2021-2026)

Table 33. Global NK-1 Receptor Antagonists Sales by Country/Region (2021-2026) & (K Units)

Table 34. Global NK-1 Receptor Antagonists Sales Market Share by Country/Region (2021-2026)

Table 35. Global NK-1 Receptor Antagonists Revenue by Country/Region (2021-2026) & (\$ millions)

Table 36. Global NK-1 Receptor Antagonists Revenue Market Share by Country/Region (2021-2026)

Table 37. Americas NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units)

Table 38. Americas NK-1 Receptor Antagonists Sales Market Share by Country (2021-2026)

Table 39. Americas NK-1 Receptor Antagonists Revenue by Country (2021-2026) & (\$ millions)

Table 40. Americas NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units)

Table 41. Americas NK-1 Receptor Antagonists Sales by Application (2021-2026) & (K Units)

Table 42. APAC NK-1 Receptor Antagonists Sales by Region (2021-2026) & (K Units)

Table 43. APAC NK-1 Receptor Antagonists Sales Market Share by Region (2021-2026)

Table 44. APAC NK-1 Receptor Antagonists Revenue by Region (2021-2026) & (\$

millions)

Table 45. APAC NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units)

Table 46. APAC NK-1 Receptor Antagonists Sales by Application (2021-2026) & (K Units)

Table 47. Europe NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units)

Table 48. Europe NK-1 Receptor Antagonists Revenue by Country (2021-2026) & (\$ millions)

Table 49. Europe NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units)

Table 50. Europe NK-1 Receptor Antagonists Sales by Application (2021-2026) & (K Units)

Table 51. Middle East & Africa NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units)

Table 52. Middle East & Africa NK-1 Receptor Antagonists Revenue Market Share by Country (2021-2026)

Table 53. Middle East & Africa NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units)

Table 54. Middle East & Africa NK-1 Receptor Antagonists Sales by Application (2021-2026) & (K Units)

Table 55. Key Market Drivers & Growth Opportunities of NK-1 Receptor Antagonists

Table 56. Key Market Challenges & Risks of NK-1 Receptor Antagonists

Table 57. Key Industry Trends of NK-1 Receptor Antagonists

Table 58. NK-1 Receptor Antagonists Raw Material

Table 59. Key Suppliers of Raw Materials

Table 60. NK-1 Receptor Antagonists Distributors List

Table 61. NK-1 Receptor Antagonists Customer List

Table 62. Global NK-1 Receptor Antagonists Sales Forecast by Region (2027-2032) & (K Units)

Table 63. Global NK-1 Receptor Antagonists Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 64. Americas NK-1 Receptor Antagonists Sales Forecast by Country (2027-2032) & (K Units)

Table 65. Americas NK-1 Receptor Antagonists Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 66. APAC NK-1 Receptor Antagonists Sales Forecast by Region (2027-2032) & (K Units)

Table 67. APAC NK-1 Receptor Antagonists Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 68. Europe NK-1 Receptor Antagonists Sales Forecast by Country (2027-2032) & (K Units)

- Table 69. Europe NK-1 Receptor Antagonists Revenue Forecast by Country (2027-2032) & (\$ millions)
- Table 70. Middle East & Africa NK-1 Receptor Antagonists Sales Forecast by Country (2027-2032) & (K Units)
- Table 71. Middle East & Africa NK-1 Receptor Antagonists Revenue Forecast by Country (2027-2032) & (\$ millions)
- Table 72. Global NK-1 Receptor Antagonists Sales Forecast by Type (2027-2032) & (K Units)
- Table 73. Global NK-1 Receptor Antagonists Revenue Forecast by Type (2027-2032) & (\$ millions)
- Table 74. Global NK-1 Receptor Antagonists Sales Forecast by Application (2027-2032) & (K Units)
- Table 75. Global NK-1 Receptor Antagonists Revenue Forecast by Application (2027-2032) & (\$ millions)
- Table 76. Merck Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
- Table 77. Merck NK-1 Receptor Antagonists Product Portfolios and Specifications
- Table 78. Merck NK-1 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 79. Merck Main Business
- Table 80. Merck Latest Developments
- Table 81. TerSera Therapeutics Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
- Table 82. TerSera Therapeutics NK-1 Receptor Antagonists Product Portfolios and Specifications
- Table 83. TerSera Therapeutics NK-1 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 84. TerSera Therapeutics Main Business
- Table 85. TerSera Therapeutics Latest Developments
- Table 86. Helsinn Healthcare Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
- Table 87. Helsinn Healthcare NK-1 Receptor Antagonists Product Portfolios and Specifications
- Table 88. Helsinn Healthcare NK-1 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 89. Helsinn Healthcare Main Business
- Table 90. Helsinn Healthcare Latest Developments
- Table 91. Heron Therapeutics Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 92. Heron Therapeutics NK-1 Receptor Antagonists Product Portfolios and Specifications

Table 93. Heron Therapeutics NK-1 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 94. Heron Therapeutics Main Business

Table 95. Heron Therapeutics Latest Developments

Table 96. Sandoz Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 97. Sandoz NK-1 Receptor Antagonists Product Portfolios and Specifications

Table 98. Sandoz NK-1 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 99. Sandoz Main Business

Table 100. Sandoz Latest Developments

Table 101. Glenmark Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 102. Glenmark NK-1 Receptor Antagonists Product Portfolios and Specifications

Table 103. Glenmark NK-1 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 104. Glenmark Main Business

Table 105. Glenmark Latest Developments

Table 106. Torrent Pharmaceuticals Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 107. Torrent Pharmaceuticals NK-1 Receptor Antagonists Product Portfolios and Specifications

Table 108. Torrent Pharmaceuticals NK-1 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 109. Torrent Pharmaceuticals Main Business

Table 110. Torrent Pharmaceuticals Latest Developments

Table 111. Sterisience Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 112. Sterisience NK-1 Receptor Antagonists Product Portfolios and Specifications

Table 113. Sterisience NK-1 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 114. Sterisience Main Business

Table 115. Sterisience Latest Developments

Table 116. Mylan Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 117. Mylan NK-1 Receptor Antagonists Product Portfolios and Specifications

Table 118. Mylan NK-1 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 119. Mylan Main Business

Table 120. Mylan Latest Developments

Table 121. Fresenius Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 122. Fresenius NK-1 Receptor Antagonists Product Portfolios and Specifications

Table 123. Fresenius NK-1 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 124. Fresenius Main Business

Table 125. Fresenius Latest Developments

Table 126. MSN Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 127. MSN NK-1 Receptor Antagonists Product Portfolios and Specifications

Table 128. MSN NK-1 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 129. MSN Main Business

Table 130. MSN Latest Developments

Table 131. Teva Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 132. Teva NK-1 Receptor Antagonists Product Portfolios and Specifications

Table 133. Teva NK-1 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 134. Teva Main Business

Table 135. Teva Latest Developments

Table 136. Eugia Pharma Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 137. Eugia Pharma NK-1 Receptor Antagonists Product Portfolios and Specifications

Table 138. Eugia Pharma NK-1 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 139. Eugia Pharma Main Business

Table 140. Eugia Pharma Latest Developments

Table 141. Lupin Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 142. Lupin NK-1 Receptor Antagonists Product Portfolios and Specifications

Table 143. Lupin NK-1 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 144. Lupin Main Business

Table 145. Lupin Latest Developments

Table 146. Dr. Reddy's Laboratories Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 147. Dr. Reddy's Laboratories NK-1 Receptor Antagonists Product Portfolios and Specifications

Table 148. Dr. Reddy's Laboratories NK-1 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 149. Dr. Reddy's Laboratories Main Business

Table 150. Dr. Reddy's Laboratories Latest Developments

Table 151. Chia Tai Tianqing Pharmaceutical Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 152. Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications

Table 153. Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 154. Chia Tai Tianqing Pharmaceutical Main Business

Table 155. Chia Tai Tianqing Pharmaceutical Latest Developments

Table 156. Qilu Pharmaceutical Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 157. Qilu Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications

Table 158. Qilu Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 159. Qilu Pharmaceutical Main Business

Table 160. Qilu Pharmaceutical Latest Developments

Table 161. Beijing Sihuan Pharmaceutical Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 162. Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications

Table 163. Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 164. Beijing Sihuan Pharmaceutical Main Business

Table 165. Beijing Sihuan Pharmaceutical Latest Developments

Table 166. Yichang Humanwell Pharmaceutical Basic Information, NK-1 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 167. Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Product Portfolios and Specifications

Table 168. Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 169. Yichang Humanwell Pharmaceutical Main Business

Table 170. Yichang Humanwell Pharmaceutical Latest Developments

Table 171. Hansoh Pharma Basic Information, NK-1 Receptor Antagonists  
Manufacturing Base, Sales Area and Its Competitors

Table 172. Hansoh Pharma NK-1 Receptor Antagonists Product Portfolios and  
Specifications

Table 173. Hansoh Pharma NK-1 Receptor Antagonists Sales (K Units), Revenue (\$  
Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 174. Hansoh Pharma Main Business

Table 175. Hansoh Pharma Latest Developments

## List Of Figures

### LIST OF FIGURES

Figure 1. Picture of NK-1 Receptor Antagonists

Figure 2. NK-1 Receptor Antagonists Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global NK-1 Receptor Antagonists Sales Growth Rate 2021-2032 (K Units)

Figure 7. Global NK-1 Receptor Antagonists Revenue Growth Rate 2021-2032 (\$ millions)

Figure 8. NK-1 Receptor Antagonists Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 9. NK-1 Receptor Antagonists Sales Market Share by Country/Region (2025)

Figure 10. NK-1 Receptor Antagonists Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 11. Product Picture of Aprepitant

Figure 12. Product Picture of Rolapitant

Figure 13. Product Picture of Fosaprepitant

Figure 14. Product Picture of Netupitant

Figure 15. Product Picture of Maropitant

Figure 16. Product Picture of Other

Figure 17. Global NK-1 Receptor Antagonists Sales Market Share by Type in 2026

Figure 18. Global NK-1 Receptor Antagonists Revenue Market Share by Type (2021-2026)

Figure 19. NK-1 Receptor Antagonists Consumed in Chemotherapy-induced Nausea and Vomiting (CINV)

Figure 20. Global NK-1 Receptor Antagonists Market: Chemotherapy-induced Nausea and Vomiting (CINV) (2021-2026) & (K Units)

Figure 21. NK-1 Receptor Antagonists Consumed in Postoperative Nausea and Vomiting (PONV)

Figure 22. Global NK-1 Receptor Antagonists Market: Postoperative Nausea and Vomiting (PONV) (2021-2026) & (K Units)

Figure 23. NK-1 Receptor Antagonists Consumed in Other

Figure 24. Global NK-1 Receptor Antagonists Market: Other (2021-2026) & (K Units)

Figure 25. Global NK-1 Receptor Antagonists Sale Market Share by Application (2025)

Figure 26. Global NK-1 Receptor Antagonists Revenue Market Share by Application in 2026

- Figure 27. NK-1 Receptor Antagonists Sales by Company in 2026 (K Units)
- Figure 28. Global NK-1 Receptor Antagonists Sales Market Share by Company in 2026
- Figure 29. NK-1 Receptor Antagonists Revenue by Company in 2026 (\$ millions)
- Figure 30. Global NK-1 Receptor Antagonists Revenue Market Share by Company in 2026
- Figure 31. Global NK-1 Receptor Antagonists Sales Market Share by Geographic Region (2021-2026)
- Figure 32. Global NK-1 Receptor Antagonists Revenue Market Share by Geographic Region in 2026
- Figure 33. Americas NK-1 Receptor Antagonists Sales 2021-2026 (K Units)
- Figure 34. Americas NK-1 Receptor Antagonists Revenue 2021-2026 (\$ millions)
- Figure 35. APAC NK-1 Receptor Antagonists Sales 2021-2026 (K Units)
- Figure 36. APAC NK-1 Receptor Antagonists Revenue 2021-2026 (\$ millions)
- Figure 37. Europe NK-1 Receptor Antagonists Sales 2021-2026 (K Units)
- Figure 38. Europe NK-1 Receptor Antagonists Revenue 2021-2026 (\$ millions)
- Figure 39. Middle East & Africa NK-1 Receptor Antagonists Sales 2021-2026 (K Units)
- Figure 40. Middle East & Africa NK-1 Receptor Antagonists Revenue 2021-2026 (\$ millions)
- Figure 41. Americas NK-1 Receptor Antagonists Sales Market Share by Country in 2026
- Figure 42. Americas NK-1 Receptor Antagonists Revenue Market Share by Country (2021-2026)
- Figure 43. Americas NK-1 Receptor Antagonists Sales Market Share by Type (2021-2026)
- Figure 44. Americas NK-1 Receptor Antagonists Sales Market Share by Application (2021-2026)
- Figure 45. United States NK-1 Receptor Antagonists Revenue Growth 2021-2026 (\$ millions)
- Figure 46. Canada NK-1 Receptor Antagonists Revenue Growth 2021-2026 (\$ millions)
- Figure 47. Mexico NK-1 Receptor Antagonists Revenue Growth 2021-2026 (\$ millions)
- Figure 48. Brazil NK-1 Receptor Antagonists Revenue Growth 2021-2026 (\$ millions)
- Figure 49. APAC NK-1 Receptor Antagonists Sales Market Share by Region in 2026
- Figure 50. APAC NK-1 Receptor Antagonists Revenue Market Share by Region (2021-2026)
- Figure 51. APAC NK-1 Receptor Antagonists Sales Market Share by Type (2021-2026)
- Figure 52. APAC NK-1 Receptor Antagonists Sales Market Share by Application (2021-2026)
- Figure 53. China NK-1 Receptor Antagonists Revenue Growth 2021-2026 (\$ millions)
- Figure 54. Japan NK-1 Receptor Antagonists Revenue Growth 2021-2026 (\$ millions)

Figure 55. South Korea NK-1 Receptor Antagonists Revenue Growth 2021-2026 (\$ millions)

Figure 56. Southeast Asia NK-1 Receptor Antagonists Revenue Growth 2021-2026 (\$ millions)

Figure 57. India NK-1 Receptor Antagonists Revenue Growth 2021-2026 (\$ millions)

Figure 58. Australia NK-1 Receptor Antagonists Revenue Growth 2021-2026 (\$ millions)

Figure 59. China Taiwan NK-1 Receptor Antagonists Revenue Growth 2021-2026 (\$ millions)

Figure 60. Europe NK-1 Receptor Antagonists Sales Market Share by Country in 2026

Figure 61. Europe NK-1 Receptor Antagonists Revenue Market Share by Country (2021-2026)

Figure 62. Europe NK-1 Receptor Antagonists Sales Market Share by Type (2021-2026)

Figure 63. Europe NK-1 Receptor Antagonists Sales Market Share by Application (2021-2026)

Figure 64. Germany NK-1 Receptor Antagonists Revenue Growth 2021-2026 (\$ millions)

Figure 65. France NK-1 Receptor Antagonists Revenue Growth 2021-2026 (\$ millions)

Figure 66. UK NK-1 Receptor Antagonists Revenue Growth 2021-2026 (\$ millions)

Figure 67. Italy NK-1 Receptor Antagonists Revenue Growth 2021-2026 (\$ millions)

Figure 68. Russia NK-1 Receptor Antagonists Revenue Growth 2021-2026 (\$ millions)

Figure 69. Middle East & Africa NK-1 Receptor Antagonists Sales Market Share by Country (2021-2026)

Figure 70. Middle East & Africa NK-1 Receptor Antagonists Sales Market Share by Type (2021-2026)

Figure 71. Middle East & Africa NK-1 Receptor Antagonists Sales Market Share by Application (2021-2026)

Figure 72. Egypt NK-1 Receptor Antagonists Revenue Growth 2021-2026 (\$ millions)

Figure 73. South Africa NK-1 Receptor Antagonists Revenue Growth 2021-2026 (\$ millions)

Figure 74. Israel NK-1 Receptor Antagonists Revenue Growth 2021-2026 (\$ millions)

Figure 75. Turkey NK-1 Receptor Antagonists Revenue Growth 2021-2026 (\$ millions)

Figure 76. GCC Countries NK-1 Receptor Antagonists Revenue Growth 2021-2026 (\$ millions)

Figure 77. Manufacturing Cost Structure Analysis of NK-1 Receptor Antagonists in 2026

Figure 78. Manufacturing Process Analysis of NK-1 Receptor Antagonists

Figure 79. Industry Chain Structure of NK-1 Receptor Antagonists

Figure 80. Channels of Distribution

Figure 81. Global NK-1 Receptor Antagonists Sales Market Forecast by Region (2027-2032)

Figure 82. Global NK-1 Receptor Antagonists Revenue Market Share Forecast by Region (2027-2032)

Figure 83. Global NK-1 Receptor Antagonists Sales Market Share Forecast by Type (2027-2032)

Figure 84. Global NK-1 Receptor Antagonists Revenue Market Share Forecast by Type (2027-2032)

Figure 85. Global NK-1 Receptor Antagonists Sales Market Share Forecast by Application (2027-2032)

Figure 86. Global NK-1 Receptor Antagonists Revenue Market Share Forecast by Application (2027-2032)

## I would like to order

Product name: Global NK-1 Receptor Antagonists Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G104CCE1482FEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G104CCE1482FEN.html>